The Brain Tumor Research Center at the University of California, San Francisco has initiated a Phase 2 clinical trial of an investigational vaccine for treating glioma, a recurrent cancer of the central nervous system that occurs primarily in the brain.The primary objective of the new trial is to evaluate overall survival in patients receiving vitespen vaccination (trademarked as Oncophage).
